The preliminary outcome of 11 patients with advanced relapsed/refractory non-small cell lung cancer (NSCLC) who received anti-EGFR CAR-T cells at a dose of 0.45–1.09 × 107 CAR+ cells/kg alone or following investigator’s choice conditioning chemotherapy showed that the treatment was well-tolerated without severe toxicity (Feng et al., 2016). Here, EGFR is linked to non-small cell lung carcinoma.